Effect of Black Tea Consumption on Blood Cholesterol: A Meta-Analysis of 15 Randomized Controlled Trials



Dongmei Wang^{1,9}, Canhuang Chen^{2,9}, Yu Wang³, Jiaxing Liu², Rongkai Lin⁴*

1 Department of Laboratory Medicine, No.161 Hospital of PLA, Wuhan City, Hubei Province, PR. China, 2 Department of Cardiology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 3 Health Management Center, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 4 Department of Urology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 4 Department of Urology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 4 Department of Urology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 4 Department of Urology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China, 4 Department of Urology, No. 180 Hospital of PLA, Quanzhou City, Fujian Province, PR. China

Abstract

Background: The results of the studies that have investigated the effects of black tea on blood cholesterol are inconsistent. The aim of this study is to quantitatively assess the effects of black tea on cholesterol concentrations.

Methods: PubMed, Embase, MEDLINE, and Cochrane Library (through to July 2014) were searched for randomized controlled trials (RCTs) designed to investigate the effect of black tea on blood cholesterol concentrations. The study quality was assessed by the Jadad scoring criteria. Pooled effect of black tea consumption on blood cholesterol concentrations was evaluated by fixed-effects or random-effects model. Meta-regression analyses were conducted to estimate dose effects of black tea polyphenols on concentrations of blood cholesterol. Subgroup and sensitivity analyses were performed to assess the potential source of heterogeneity.

Results: The consumption of black tea did not significantly lower TC concentrations either in healthy subjects or patients with coronary artery diseases based on both fixed-effects and random-effects analysis. No significant change was observed in HDL-C concentrations in healthy participants or in subjects with coronary artery disease supplemented with black tea when compared with control participants. The pooled net change of LDL-C in healthy participants was -5.57 mg/dL (95% Cl, -9.49 to -1.66 mg/dL; P = 0.005) in fixed-effects analysis and -4.56 (95% Cl, -10.30 to 1.17 mg/dL; P = 0.12) in random-effects analysis. No significant net change was observed in LDL-C concentrations in patients with coronary artery disease. Subgroup and sensitivity did not significantly influence the overall outcomes of this meta-analysis. No significant dose effects of black tea polyphenols on blood cholesterol concentrations were detected in meta-regression analyses.

Conclusion: The meta-analysis suggests that the consumption of black tea might not have beneficial effects on concentrations of TC, HDL-C, and LDL-C. Further high quality RCTs are needed to definitively draw a causal interpretation of the findings.

Citation: Wang D, Chen C, Wang Y, Liu J, Lin R (2014) Effect of Black Tea Consumption on Blood Cholesterol: A Meta-Analysis of 15 Randomized Controlled Trials. PLoS ONE 9(9): e107711. doi:10.1371/journal.pone.0107711

Editor: Natalie Walker, The National Institute for Health Innovation, New Zealand

Received March 8, 2014; Accepted August 14, 2014; Published September 19, 2014

Copyright: © 2014 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by the Risk Management of the Chronic Disease and Construction of the Health Information Platform in Quanzhou Area (grant number: 2013Z56). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

- * Email: rongkailin180@gmail.com
- These authors contributed equally to this work.
- ¶ DMW and CHC are joint first authors on this work.

Introduction

Currently, cardiovascular diseases (CVD) account for almost 50% of non communicable diseases, which have exceeded communicable diseases as the major disease burden worldwide. CVD is responsible for 17.3 million deaths every year, and remains the primary global death cause [1,2]. It is projected that 377 billion will be saved by 10% reduction of CVD mortality from 2011 to 2025 [3]. Low high-density lipoprotein-cholesterol (HDL-C) concentrations and high total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) concentrations are the major risk factors of CVD [4–8]. A recent study suggests that a 1% reduction of cholesterol can decrease the risk of CVD by 3% [9], whereas hyperlipidemia may increase the heart attack risk by 3-fold [10], indicating that the effective regulation of cholesterol metabolism

will reduce the burden of CVD. Accumulating data suggest that healthy foods consumption can significantly lower TC concentration [11], and increase HDL-C concentrations [12]. Therefore, growing attention has been devoted to the dietary intervention on the prevention and treatment of CVD.

Tea, derived from the plant Camellia sinensis, is currently consumed worldwide and considered as a major source of flavonoid consumption in the US diet [13]. Tea is mainly divided into three types, such as green tea, black tea and oolong tea. In general, green tea is produced by non-fermented leaves, while black tea and oolong tea are made from the fermented leaves and partly fermented leaves, respectively [14]. A previous metaanalysis on the basis of 14 randomized controlled trials (RCTs) revealed that green tea consumption can significantly reduce plasma LDL-C and TC concentrations [15]. In addition, the meta-analysis based on observational studies found that tea consumption including green tea, black tea, or oolong tea is significantly associated with the reduction of CVD risk [16]. To date, several RCTs have been designed to evaluate the effects of black tea consumption on blood cholesterol concentrations, with inconsistent results. Although two previous meta-analyses had been conducted to investigate the effect of black tea on blood cholesterol concentrations, one study only included two RCTs when pooling the effects of black tea on TC concentrations [17], while the other study conducted their meta-analysis based on the combined population with different health status [18]. Therefore, we performed this meta-analysis to further assess the effects of black tea on the PRISMA guidelines.

Methods

Literature search

We searched and reviewed the database of PubMed (through to July 2014), Embase (through to July 2014), MEDLINE (through to July 2014), the Cochrane Library (through to July 2014) for RCTs designed to evaluate the effect of black tea on blood cholesterol concentrations in human subjects. All databases were searched using the following terms limited in title or abstract: black tea, black tea extract, catechin, catechins, EGCG, camellia sinensis, theaflavin or tea polyphenols. The results of the searching were restricted to RCTs in human subjects. In addition, we scanned the reference lists of correlated reviews to further identify potential additional articles. The searching process was performed by DM Wang, and CH Chen, and any disagreements were resolved by a third reviewer if needed. A separate search strategy, specific for each electronic database could be found in the Supplemental information (Appendix S1).

Study selection

Studies were selected in this meta-analysis when meeting the following inclusion criteria: 1) the original study used an appropriate control group for black tea or black tea extract intervention group; 2) the study was a parallel- or crossover-design RCT in humans; 3) subjects ingested black tea or black tea extracts for ≥ 2 weeks; 4) the study did not use a multi-component treatment containing black tea in the intervention group; 5) the baseline and endpoint values for concentrations of TC, HDL-C, LDL-C or mean differences with either 95% CI, SEM or SD values were shown in the studies.

When necessary, the main authors were contacted for additional information.

Quality assessment

The quality of the included studies was independently assessed by two authors according to the Jadad scoring criteria: 1) randomization (the trial was described as randomized); 2) reporting the methods of generation of random numbers (using random numbers table, computer, tossed coins or shuffled cards, etc); 3) double-blinding study-design (researcher and participant masking); 4) using a proper allocation concealment; and 5) clearly reporting the number and reasons for dropouts. The included studies achieved one point when meeting the standard of each specific item. The possible score ranged from 0 to 5 (highest quality level) [19]. The high-quality study was with a score of ≥ 4 , whereas the low quality study was with a score of < 4.

Data extraction

The standardized data extraction form of the meta-analysis included the following items: 1) characteristics of each study including the first author, publication year, country of the population, sample size, design of study, duration of study, intervention dose, intervention type and diet type; 2) population information including baseline health status, baseline concentrations of TC, HDL-C, and LDL-C, body mass index (BMI), and mean age of the population; 3) net changes of concentrations of TC, HDL-C, or LDL-C for each group; and 4) all values of cholesterol concentrations were converted to mg/dL (conversion factor: 1 mg/dL = 0.0259 mmol/L) [20]. The data extraction process was independently performed by two authors, and any disagreements were resolved by a third author.

Statistical analysis

Current meta-analysis was conducted using STATA software (Version 11; StataCorp, College Station, TX). The effective size of intervention was defined as weighted mean difference with its 95% CIs of TC, HDL-C, and LDL-C concentrations. The statistical heterogeneity between individual included trials results was evaluated by Cochran's test and the I^2 statistics. The Cochran's test P value of <0.10 or the I^2 value of >50% suggested a significant heterogeneity between the included studies [21]. A random-effects model (I–V heterogeneity) was used if a significant statistical heterogeneity was detected. Otherwise, a fixed-effects (Inverse Variance) model was applied in the meta-analysis. To provide more credible and detailed results of the data synthesis, we showed the results calculated from both fixed-effects and random-effects models and make the conclusion based on both of the two models.

SD values were indirectly calculated from SEM, *P*-values, 95% CIs, or t-values if they were missing in the original studies. As suggested by Follmann [22], we assumed that the correlation coefficient is 0.5 between the initial and final values.

Subgroup analyses including baseline BMI value, study design, intervention type, intervention duration, black tea polyphenol dose, and study quality were performed to explore the potential source of heterogeneity between the RCTs. Sensitivity analyses were conducted in accordance with the Systematic Review of Interventions Handbook of Cochrane software. Meta-regression analyses were conducted to evaluate the dose-effect of black tea polyphenols on concentrations of TC, HDL-C, or LDL-C. Publication bias in this meta-analysis was evaluated by the funnel plots and Egger's test.

Results

Literature Search Results

Figure 1 showed the detailed processes of selecting the relevant studies. The initial searching yielded a total of 735 potential reports with 701 articles being excluded due to either duplication or being irrelevant to this meta-analysis by carefully reviewing the titles and abstracts of each study. Thus, the remaining 34 articles underwent an in-depth examination. Of these, 7 studies did not report the data of concentrations of TC, HDL-C, or LDL-C, 6 studies had short treatment duration (<2 weeks), and 6 studies used a multi-component supplement containing black tea in intervention group. At last, 15 articles were ultimately included in current meta-analysis [23–37].

Study characteristics

A summary of study characteristics for each included trial was presented in **Table 1**. The sample size of all included trials ranged



Figure 1. Flow diagram showing the number of studies screened, assessed for eligibility, and included in the metaanalysis.

doi:10.1371/journal.pone.0107711.g001

from 15 to 72. Ten of 15 included studies used parallel design, while the remaining 5 trials used crossover design. Of the 15 trials included in our meta-analysis, 11 selected healthy subjects, 2 included the patients with coronary artery disease, 1 included the subjects with diabetes and 1 included the participants with diabetes or with two other cardiovascular risk factors. Thirteen of the 15 included studies considered cholesterol as a primary outcome, while the remaining 2 considered cholesterol as a secondary outcome [25,29]. Of the 11 studies including healthy subjects, 5 used black tea extract as supplement, and 6 studies used black tea leaf as intervention supplement. The duration of study varied from 3 weeks to 6 months (median: 4 weeks). In addition, 8 studies provided the information of black tea polyphenols, and the polyphenols content ranged from 77.5 to 1350 mg/d (median: 351.2 mg/d). Most of the trials suggested the subjects to maintain their usual diet, whereas one study provided the same background controlled diet to the volunteers.

Data quality

Quality of each study was assessed by the Jadad score criteria and the outcome was shown in **Table 1**. Four trials [24,26,27,30] were considered to be of high-quality and 11 studies were deemed as low-quality studies. All of the high-quality RCTs used the adequate allocation concealment and double-blinding in studydesign. Of the 4 high-quality studies, one study reported the method of random number generation, and the remaining 3 were only described as randomized. Fourteen of 15 included studies reported the details related to the dropouts unless there was no dropout in the study.

Effect of black tea on blood cholesterol

As shown in **Figure 2**, the consumption of black tea did not significantly lower TC concentrations in healthy subjects based on both fixed-effects analysis (-3.76 mg/dL; 95% CI, -7.67 to 0.16 mg/dL; P=0.06) and random-effects analysis (-2.85 mg/dL; 95% CI, -8.02 to 2.31 mg/dL; P=0.28). Black tea

consumption did not significantly affect mean difference change of TC concentrations in patients with coronary artery disease. No significant change was observed in HDL-C concentrations in healthy participants or in subjects with coronary artery disease supplemented with black tea based on both fixed-effects and random-effects analysis when compared with control participants (Figure 3). The net change of LDL-C in healthy participants was pooled based on 11 comparisons, and the pooled weighted mean difference was -5.57 mg/dL (95% CI, -9.49 to -1.66 mg/dL; P = 0.005; Figure 4) in fixed-effects analysis and -4.56 (95% CI, -10.30 to 1.17 mg/dL; P = 0.12; Figure 4) in random-effects analysis. Both the fixed-effects and random-effects analysis were conducted to investigate the effects of black tea on LDL-C concentrations in patients with coronary artery disease, and no significant net change was found (Figure 4). In addition, black tea intervention did not show a significant effect on both HDL-C and LDL-C concentrations in participants with diabetes or with two other cardiovascular risk factors (Figure 3 and 4).

Subgroup analyses were conducted to further investigate the influences of baseline BMI, design of study, intervention type, intervention duration, dose of black tea polyphenol, and study quality on the effects of black tea on concentrations of TC, HDL-C and LDL-C in healthy subjects (Table 2-4 and Figure S1-**S6**). The intervention duration was categorized as a long-term subgroup (>4 weeks) and a short-term subgroup (≤ 4 weeks). The treatment dose of black tea polyphenols was classified as either high-dose (\geq 351.2 mg/d) or low-dose (\leq 351.2 mg/d). As shown in Table 2, subgroup analyses of TC indicated that black tea significantly decreased TC concentrations in crossover design RCTs. However, no significant net change of TC concentrations was detected in other subgroup analyses. Subgroup analyses of HDL-C did not significantly alter the overall effects of black tea on HDL-C concentrations in healthy subjects (Table 3). In the subgroup analyses of LDL-C, the results showed that black tea only significantly lower LDL-C concentrations in the subgroup of studies with high Jadad score based on both fixed-effects and random-effects analysis (Table 4).

Meta-regression analyses indicated a non-significant doseresponsive effects of black tea polyphenols on TC concentrations (P for trend = 0.61), HDL-C concentrations (P for trend = 0.92) or LDL-C concentrations (P for trend = 0.83). The sensitivity analyses showed that the overall outcome of black tea on blood cholesterol concentrations were not significantly affected after imputation a correlation coefficient of 0.5. Moreover, systematically removing each trial during the sensitivity analyses did not significantly affect the overall outcomes of black tea on the concentration of TC, HDL-C or LDL-C (**Figure S7–S9**).

Publication bias

The funnel plots were symmetrical and the Egger's tests showed no significant publication bias in our meta-analyses of TC, HDL-C and LDL-C concentrations (Egger's test: P = 0.09, 0.38 and 0.37, respectively).

Discussion

The overall outcome of this meta-analysis suggested that black tea intake did not significantly alter concentrations of TC, HDL-C, or LDL-C in healthy subjects. The results of subgroup analyses of TC, HDL-C, and LDL-C did not significantly affect the overall outcome of the effect of black tea on these biomarkers. Although subgroup analyses of LDL-C in healthy subjects indicated that administration of black tea significantly lower LDL-C concentrations based on the studies with high Jadad socre, significant Table 1. Characteristics of the 14 randomized controlled trials included in the meta-analysis.

Author, publication year, Country	No. of subjects	Study design	Population	Duration	Tea group	Control group	BMI (kg/m²)	JadadScore	Type of diet
Bahorun, 2012, Mauritius	72	Parallel	Healthy, 25–60 years of age	12 wk	Black tea leaf (9 g/d)	Water	NR	m	Usual diet
Kubota, 2011, Japan	36	Parallel	Healthy, 52.2 \pm 11.9 years of age	12 wk	Black tea extract (1 g/d)	Placebo powder	26.2±2.1	4	Usual diet
Neyestani, 2010, Iran	46	Parallel	T2DM, 57.0±37.9 years of age	4 wk	Black tea extract (2.5 g/d in week 1, increased by 2.5 g/d for each week)	Black tea extract (2.5 g/d)	29.0±1.5	7	Usual diet
Trautwein, 2009, Netherlands	71	Parallel	Healthy, 47.5 \pm 6.7 years of age	11 wk	Black tea extract (77.5 mg/d polyphenoles)	Placebo capsules (cellulose)	23.8±2.4	S	Usual diet
Fujita, 2008, Japan	47	Parallel	Healthy with borderline hypercholesterol, 40–70 years of age	3 mo	Black tea extract (1 g/d)	Placebo tablets (dextrin)	23.1±1.5	4	Usual diet
Mukamal, 2007, USA	28	Parallel	Either diabetes or with 2 other cardiovascular risk factors, 6.6 ± 29.9 years of age	6 mo	Black tea extract (318 mg/d polyphenoles)	Water	27.7±16.8	m	Usual diet
Hodgson, 2003, Australia	22	Crossover	Healthy, 59.0 \pm 7.5 years of age	4 wk	Black tea leaf (10 g/d)	Water	27.0±2.8	2	Usual diet
Davies, 2003, USA	15	Crossover	Healthy, 53.9±9.3 years of age	3 wk	Black tea leaf (860 mg/d polyphenoles; 203 mg/d caffeine)	Placebo beverage (220 mg/d caffeine)	29.8±5.0	4	Controlled diet
Hodgson, 2002, Australia	20	Parallel	Healthy, 60.9 \pm 5.4 years of age	4 wk	Black tea leaf (10 g/d)	Water	28.0±3.2	2	Usual diet
Duffy, 2001a, USA	50	Crossover	Coronary artery disease, 54±8 years of age	4 wk	Black tea leaf (1350 mg/d polyphenoles, 270 mg/d caffeine)	Water	28.4±4.3	m	Usual diet
Duffy, 2001b, USA	49	Crossover	Coronary artery disease, 54.6±9.5 years of age	4 wk	Black tea leaf (1350 mg/d polyphenoles, 270 mg/d caffeine)	Water	30.6±6.3	ĸ	Usual diet
Author, publication year, Country (reference no.)	No. of subjects	Study design	Population	Duration	Tea group	Control group	BMI (kg/m ²)	Jadad Score	Type of diet
Princen, 1998, Netherlands	31	Parallel	Healthy, 34±12 years of age	4 wk	Black tea extract (326.4 mg/d polyphenoles)	Water	24±3	2	Usual diet
Ishikawa, 1997, Japan	22	Parallel	Healthy, 22±1 years of age	4 wk	Black tea leaf (376 mg/d polyphenoles)	Water	22.8±2.7	2	Usual diet
Bingham, 1997, UK	65	Crossover	Healthy, 40±15 years of age	4 wk	Black tea leaf (six tea bags/d)	Placebo	NR	2	Usual diet
Van het Hof, 1997, Netherland	31	Parallel	Healthy, 20–61 years of age	4 wk	Black tea leaf (215 mg/d polyphenols)	Water	23.8±1.8	2	Usual diet
Abbreviation: BMI, body The usual diet was simik used direct measuring n doi:10.1371/journal.pone	r mass index; NR, not ar to a conventional d nethod. 3.0107711.t001	reported; T2DM, typ diet. The studies by N	e 2 diabetes mellitus. leyestani (2010), Duffy (2011a), Duffy [,]	(2011b) and Bing	ham (1997) used LDL concentr	rations calculated base	d on Friedewald's	formula, and the r	emaining studies

Study	Fixed-effects analysis	WMD (95% Cl) Weight %
Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Hodgson 2003 Davies 2003 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 36.0%, p = 0.107		-0.10 (-21.97, 21.77) 3.21 17.50 (-7.02, 42.02) 2.55 6.17 (-9.85, 22.19) 5.98 -4.64 (-17.39, 8.11) 9.44 -20.85 (-36.94, -4.76) 5.92 -3.93 (-14.63, 6.77) 13.39 -12.50 (-22.62, -2.38) 14.96 7.72 (-13.68, 29.12) 3.35 6.18 (-5.61, 17.97) 11.03 8.11 (-15.14, 31.36) 2.84 -2.70 (-17.30, 11.90) 7.19 -7.33 (-16.06, 1.39) 20.15 -3.76 (-7.67, 0.16) 100.00
T2DM Neyestani 2010 Subtotal (I-squared = .%, p = .)		0.00 (-6.31, 6.31) 100.00 0.00 (-6.31, 6.31) 100.00
Coronary artery disease Duffy 2001a Duffy 2001b Subtotal (I-squared = 0.0%, p = 0.754)		-3.86 (-16.06, 8.34) 53.62 -1.00 (-14.12, 12.12) 46.38 -2.53 (-11.47, 6.40) 100.00
-42	0	42
Study	Random-effects analysis	WMD (95% CI) Weight %
Study Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Hodgson 2003 Davies 2003 Davies 2003 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 36.0%, p = 0.102	Random-effects analysis	WMD (95% C) Weight % -0.10 (-21.97, 21.77) 4.55 17.50 (-7.02, 42.02) 3.76 6.17 (-9.85, 22.19) 7.33 -4.64 (-17.39, 8.11) 9.88 -20.85 (-36.94, -4.76) 7.28 -3.93 (-14.63, 6.77) 12.01 -12.50 (-22.62, -2.38) 12.70 7.72 (-13.68, 29.12) 4.72 6.18 (-5.61, 17.97) 10.82 8.11 (-15.14, 31.36) 4.12 -2.70 (-17.30, 11.90) 8.32 -7.33 (-16.06, 1.39) 14.52 -2.85 (-8.02, 2.31) 100.00
Study Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Hodgson 2003 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 36.0%, p = 0.102 . T2DM Neyestani 2010 Subtotal (I-squared = .%, p = .)	Random-effects analysis	WMD (95% C)) Weight %
Study Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Hodgson 2003 Davies 2003 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 36.0%, p = 0.102 Coronary artery disease Duffy 2001a Duffy 2001b Subtotal (I-squared = 0.0%, p = 0.754)	Random-effects analysis	WMD (95% Cl) Weight % -0.10 (-21.97, 21.77) 4.55 17.50 (-7.02, 42.02) 3.76 6.17 (-9.85, 22.19) 7.33 -4.64 (-17.39, 8.11) 9.88 -20.85 (-36.94, -4.76) 7.28 -3.93 (-14.63, 6.77) 12.01 -12.50 (-22.62, -2.38) 12.70 7.72 (-13.68, 29.12) 4.72 6.18 (-5.61, 17.97) 10.82 8.11 (-15.14, 31.36) 4.12 -2.70 (-17.30, 11.90) 8.32 -7.33 (-16.06, 1.39) 14.52 -2.85 (-8.02, 2.31) 100.00 0.00 (-6.31, 6.31) 100.00 0.00 (-6.31, 6.31) 100.00 -3.86 (-16.06, 8.34) 53.62 -1.00 (-14.12, 12.12) 46.38 -2.53 (-11.47, 6.40) 100.00

Figure 2. Meta-analysis of effects of black tea on concentrations of total cholesterol (TC). A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixed-effects or random-effects model. WMD, weighted mean difference. doi:10.1371/journal.pone.0107711.g002

heterogeneity was found in this subgroup. Due to the limited number of included studies, we could not conduct subgroup analysis to confirm the effects of black tea on blood cholesterol concentrations in subjects with T2DM and coronary artery diseases and thus these results should be confirmed by more RCTs in the future.

Study	Fixed-effects analysis	WMD (95% CI) Weight %
Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 0.0%, p = 0.5		10.10 (-4.90, 25.10) 0.75 -7.30 (-15.94, 1.34) 2.26 0.38 (-8.76, 9.52) 2.02 0.39 (-6.26, 7.04) 3.81 -1.93 (-8.91, 5.05) 3.47 0.40 (-1.40, 2.20) 51.87 0.77 (-7.99, 9.53) 2.20 0.78 (-2.21, 3.77) 18.83 -5.79 (-17.10, 5.52) 1.32 -1.16 (-7.00, 4.68) 4.95 -3.87 (-8.31, 0.57) 8.54 -0.23 (-1.53, 1.07) 100.00
T2DM Neyestani 2010 Subtotal (I-squared = .%, p = .)	\$	3.86 (2.62, 5.10) 100.00 3.86 (2.62, 5.10) 100.00
Either T2DM or with 2 other CVD risk Mukamal 2007 Subtotal (I-squared = .%, p = .)	k factors	-0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00
Coronary artery disease Duffy 2001a Duffy 2001b Subtotal (I-squared = 0.0%, p = 0.8	09)	0.00 (-6.05, 6.05) 44.13 1.00 (-4.38, 6.38) 55.87 0.56 (-3.46, 4.58) 100.00
	0	25.1
Study	Random-effects analysis	WMD (95% Cl) Woight %
		WWD (55 % CI) Weight %
Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Bingham 1997 Van het Hof 1997 Subtotal (I-squared = 0.0%, p = 0.5		10.10 (4.90, 25.10) 0.75 -7.30 (15.94, 1.34) 2.26 0.38 (-8.76, 9.52) 2.02 0.39 (-6.26, 7.04) 3.81 -1.93 (-6.26, 7.04) 3.81 -1.93 (-6.91, 5.05) 3.47 0.40 (-1.40, 2.20) 51.87 0.77 (-7.99, 9.53) 2.20 0.78 (-2.21, 3.77) 18.83 -5.79 (-17.10, 5.52) 1.32 -1.16 (-7.00, 4.68) 4.95 -3.87 (-8.31, 0.57) 8.54 -0.23 (-1.53, 1.07) 100.00
Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Wan het Hof 1997 Subtotal (I-squared = 0.0%, p = 0.5		10.10 (-4.90, 25.10) 0.75 -7.30 (-15.94, 1.34) 2.26 0.38 (-8.76, 9.52) 2.02 0.39 (-6.26, 7.04) 3.81 -1.93 (-8.91, 5.05) 3.47 0.40 (-1.40, 2.20) 51.87 0.77 (-7.99, 9.53) 2.20 0.78 (-2.21, 3.77) 18.83 -5.79 (-17.10, 5.52) 1.32 -1.16 (-7.00, 4.68) 4.95 -3.87 (-8.31, 0.57) 8.54 -0.23 (-1.53, 1.07) 100.00 3.86 (2.62, 5.10) 100.00
Healthy Bahorun 2012 (Male) Bahorun 2012 (Fernale) Kubota 2011 Trautwein 2009 Fujita 2008 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Van het Hof 1997 Subtotal (I-squared = 0.0%, p = 0.5 Either T2DM or with 2 other CVD risi Mukamal 2007 Subtotal (I-squared = .%, p = .)	handom chieve analysis	10.10 (-4.90, 25.10) 0.75 -7.30 (-15.94, 1.34) 2.26 0.38 (-8.76, 9.52) 2.02 0.39 (-6.26, 7.04) 3.81 -1.93 (-8.91, 5.05) 3.47 0.40 (-1.40, 2.20) 51.87 0.77 (-7.99, 9.53) 2.20 0.78 (-2.21, 3.77) 18.83 -5.79 (-17.10, 5.52) 1.32 -1.16 (-7.00, 4.68) 4.95 -3.87 (-8.31, 0.57) 8.54 -0.23 (-1.53, 1.07) 100.00 3.86 (2.62, 5.10) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00
Healthy Bahorun 2012 (Male) Bahorun 2012 (Female) Kubota 2011 Trautwein 2009 Fujita 2008 Davies 2003 Hodgson 2002 Princen 1998 Ishikawa 1997 Van het Hof 1997 Van het Hof 1997 Van het Hof 1997 Subtotal (I-squared = 0.0%, p = 0.5	k factors	10.10 (-4.90, 25.10) 0.75 -7.30 (-15.94, 1.34) 2.26 0.38 (-8.76, 9.52) 2.02 0.39 (-6.26, 7.04) 3.81 -1.93 (-8.91, 5.05) 3.47 0.40 (-1.40, 2.20) 51.87 0.77 (-7.99, 9.53) 2.20 0.78 (-2.21, 3.77) 18.83 -5.79 (-17.10, 5.52) 1.32 -1.16 (-7.00, 4.68) 4.95 -3.87 (-8.31, 0.57) 8.54 -0.23 (-1.53, 1.07) 100.00 3.86 (2.62, 5.10) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00 -0.60 (-8.33, 7.13) 100.00

Figure 3. Meta-analysis of effects of black tea on concentrations of high-density lipoprotein-cholesterol (HDL-C). A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixed-effects or random-effects model. WMD, weighted mean difference.

doi:10.1371/journal.pone.0107711.g003

Study	Fixed-effects analysis	WMD (95% Cl) Weight 9
lealthy		
Bahorun 2012 (Male)		-14.30 (-46.74, 18.14) 1.45
Bahorun 2012 (Female)		2.80 (-21.48, 27.08) 2.60
(ubota 2011		7.72 (-8.77, 24.21) 5.62
Frantwein 2009		.8.88 (.19.72.1.96) 13.02
Wite 2008		-0.00 (-13.12, 1.00) 13.02
		-20.05 (-36.51, -5.19) 6.24
Javies 2003		-15.30 (-24.32, -6.28) 18.80
lodgson 2002		3.86 (-13.06, 20.78) 5.34
rincen 1998		5.79 (-6.30, 17.88) 10.45
shikawa 1997		7.72 (-16.90, 32.34) 2.52
)ingham 1997		-1.93 (-19.26, 15.40) 5.10
/an het Hof 1997		-5.02 (-12.30, 2.26) 28.86
ubtotal (I-squared = 43.2%, p = 0.062)	\diamond	-5.57 (-9.49, -1.66) 100.0
2DM		
leyestani 2010		7.72 (3.26, 12.18) 100.0
ubtotal (I-squared = .%, p = .)	\diamond	7.72 (3.26, 12.18) 100.0
ither T2DM or with 2 other CVD risk factors		
lukamal 2007	•	-15.00 (-36.92, 6.92) 100.0
ubtotal (I-squared = .%, p = .)		-15.00 (-36.92, 6.92) 100.0
oronary artery disease		
uffy 2001a		0.00 (-11 38 11 38) 53 82
ouffy 2001b		-1 00 (-13 08 14 08) 46 49
where $(1 - 0.00) = 0.007$		-1.00 (-13.20, 11.20) 40.10
antital (-squarea = 0.070, p = 0.501)		-0.40 (-0.01, 1.00)
Nucles	Deadars effects and with	
Study	Random-effects analysis	WMD (95% CI) Weight %
itudy iealthy	Random-effects analysis	WMD (95% Cl) Weight %
tudy lealthy lahorun 2012 (Male) ————————————————————————————————————	Random-effects analysis	WMD (95% CI) Weight % -14.30 (-46.74, 18.14) 2.76
tudy leathy ahorun 2012 (Male) lahorun 2012 (Female)	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52
tudy lealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84
tudy ieatthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009 ujta 2008	Random-effects analysis	WMD (95% CI) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57
tudy eathy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009 ujita 2008 avies 2003	Random-effects analysis	WMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.06) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009 ujita 2008 avies 2003 odgson 2002	Random-effects analysis	WMD (95% CI) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 774
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttwein 2009 ujita 2008 avies 2003 odgson 2002 rincen 1998	Random-effects analysis	VVMD (95% Cl) VVeight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1-96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 11.54 5.79 (-6.30, 17.88) 11.54
tudy eatthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009 jita 2008 avies 2003 odgson 2002 rincen 1998 bitkawa 1997	Random-effects analysis	VVMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-38.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.79 (-16.90 32) 44 44
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rautwein 2009 ujita 2008 ujita 2008 avies 2003 odgson 2002 rincen 1998 hikawa 1997	Random-effects analysis	WMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 4.93 (-20.26 -4.07) 7.02
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Fenale) ubota 2011 ubota 2011 autwein 2009 ujita 2008 avies 2003 odgson 2002 inicen 1998 hikawa 1997 ingham 1997	Random-effects analysis	VVMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.24 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.8) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 5.92 (-2.02) 7.54
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Fernale) ubota 2011 "autwein 2009 jila 2008 avies 2003 odgson 2002 tincen 1998 hinkawa 1997 ingham 1997 an het Hof 1997	Random-effects analysis	VVMD (95% Cl) Weight 9 -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttwein 2009 ujita 2008 avies 2003 odgson 2002 rincen 1998 hikawa 1997 ingham 1997 an het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062)	Random-effects analysis	VVMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1-96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.00
tudy lealthy lahorun 2012 (Male) lahorun 2012 (Female) lubota 2011 rauttwein 2009 ujita 2008 avies 2003 lodgson 2002 rincen 1998 ihikawa 1997 ingham 1997 'an het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1-96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.55 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttwein 2009 ujita 2008 avies 2003 odgson 2002 rincen 1998 hinkawa 1997 ingham 1997 an het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM eyestani 2010	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0
tudy lealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttvein 2009 ujita 2008 avies 2003 lodgson 2002 rincen 1998 thikawa 1997 ingham 1997 lan het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 ubtotal (I-squared = .%, p = .)	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.24) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0
tudy lealthy lahorun 2012 (Male) lahorun 2012 (Female) lubota 2011 rautwein 2009 ujita 2008 avies 2003 lodgson 2002 rincen 1998 shikawa 1997 iingham 1997 Yan het Hof 1997 Jubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 Jubtotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors	Random-effects analysis	WMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0
tudy lealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttwein 2009 ujita 2008 avies 2003 odgson 2002 rincen 1998 hikawa 1997 ingham 1997 fan het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 ubtotal (I-squared = .%, p = .) ther T2DM or with 2 other CVD risk factors lukamal 2007	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 -7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0
tudy lealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttvein 2009 ujita 2008 avies 2003 lodgson 2002 rincen 1998 thikawa 1997 ran het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 ubtotal (I-squared = .%, p = .) ther T2DM or with 2 other CVD risk factors lukamal 2007 ubtotal (I-squared = .%, p = .)	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 -15.00 (-36.92, 6.92) 100.0
tudy lealthy lahorun 2012 (Male) lahorun 2012 (Female) lubota 2011 rautwein 2009 ujita 2008 avies 2003 lodgson 2002 rincen 1998 shikawa 1997 iingham 1997 Yan het Hof 1997 Jubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 lubtotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors tukamal 2007 ubtotal (I-squared = .%, p = .)	Random-effects analysis	VMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1-96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.86) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 -15.00 (-36.92, 6.92) 100.0
tudy lealthy lahorun 2012 (Male) lahorun 2012 (Female) lubota 2011 rautwein 2009 ujita 2008 lodgson 2002 rincen 1998 hinkawa 1997 lingham 1997 'an het Hof 1997 vahotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 lubotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors fukamal 2007 ubtotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors fukamal 2007 ubtotal (I-squared = .%, p = .)	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 7.72 (3.26, 12.18) 100.0 0.500 (-36.92, 6.92) 100.0 -15.00 (-36.92, 6.92) 100.0 -15.00 (-11.38, 11.38) 53.82
tudy lealthy lahorun 2012 (Male) lahorun 2012 (Fernale) lubota 2011 rautwein 2009 ujita 2008 lavies 2003 lodgson 2002 rincen 1998 hinkawa 1997 lingham 1997 'an het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM leyestani 2010 lubtotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors fukamal 2007 lubtotal (I-squared = .%, p = .) ither T2DM or with 2 other CVD risk factors fukamal 2007 lubtotal (I-squared = .%, p = .)	Random-effects analysis	WMD (95% Cl) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.86) 11.54 7.72 (-16.90, 32.34) 4.41 -1.33 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.00 7.72 (3.26, 12.18) 100.00 7.72 (3.26, 12.18) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-11.38, 11.38) 53.82 -1.00 (-13.28, 11.28) 46.18
tudy lealthy ahorun 2012 (Male) ahorun 2012 (Female) ubota 2011 rauttwein 2009 ujita 2008 avies 2003 odgson 2002 rincen 1998 hikawa 1997 ingham 1997 ingham 1997 ingham 1997 ingham 1997 ingham 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM eyestani 2010 ubtotal (I-squared = -%, p = .) ther T2DM or with 2 other CVD risk factors ukamal 2007 ubtotal (I-squared = .%, p = .) ther T2DM or with 2 other CVD risk factors ukamal 2007 ubtotal (I-squared = .%, p = .) oronary artery disease uffy 2001a uffy 2001b ubtotal (I-squared = 0.0%, p = 0.907)	Random-effects analysis	WMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.74 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.00 7.72 (3.26, 12.18) 100.00 7.72 (3.26, 12.18) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.32, 6.12.18) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.32, 61.2.18) 100.00 -15.00 (-13.28, 11.28) 46.18 -0.46 (-8.81, 7.88) 100.00
tudy ealthy ahorun 2012 (Male) ahorun 2012 (Fernale) ubota 2011 auttwein 2009 ujita 2008 avies 2003 odgson 2002 inicen 1998 hikawa 1997 an het Hof 1997 ubtotal (I-squared = 43.2%, p = 0.062) 2DM eyestani 2010 ubtotal (I-squared = 43.2%, p = .) ther T2DM or with 2 other CVD risk factors ukamal 2007 ubtotal (I-squared = .%, p = .) ther T2DM or with 2 other CVD risk factors ukamal 2007 ubtotal (I-squared = .%, p = .)	Random-effects analysis	VMD (95% C) Weight % -14.30 (-46.74, 18.14) 2.76 2.80 (-21.48, 27.08) 4.52 7.72 (-8.77, 24.21) 8.01 -8.88 (-19.72, 1.96) 12.84 -20.85 (-36.51, -5.19) 8.57 -15.30 (-24.32, -6.28) 14.95 3.86 (-13.06, 20.78) 7.14 5.79 (-6.30, 17.88) 11.54 7.72 (-16.90, 32.34) 4.41 -1.93 (-19.26, 15.40) 7.49 -5.02 (-12.30, 2.26) 17.16 -4.56 (-10.30, 1.17) 100.00 7.72 (3.26, 12.18) 100.00 7.72 (3.26, 12.18) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-36.92, 6.92) 100.00 -15.00 (-13.28, 11.38) 53.82 -1.00 (-13.28, 11.28) 46.18 -0.46 (-8.81, 7.88) 100.00

Figure 4. Meta-analysis of effects of black tea on concentrations of low-density lipoprotein-cholesterol (LDL-C). A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixed-effects or random-effects model. WMD, weighted mean difference.

doi:10.1371/journal.pone.0107711.g004

Table 2. Subgroup analyses of effect of black tea on TC concentrations in healthy subjects stratified by previously defined study characteristics.

Variables	Total cholesterol (mg/dL)					
	No. of comparisons	Net chang (95% CI)	Test of heterogeneity		Р	
			P	ľ,%		
Baseline body mass index						
≥25 kg/m ²	5	-3.80 $(-9.95, 2.35)^{a}$	0.17	38.0	0.23	
		-2.03 (-10.41, 6.34) ^b			0.63	
<25 kg/m ²	4	-5.30 (-11.04, 0.44) ^a	0.06	59.7	0.07	
		-5.80 (-15.25, 3.65) ^b			0.23	
Study design						
Parallel	9	-1.81 (-6.69, 3.07) ^a	0.09	41.6	0.47	
		-0.58 (-7.46, 6.29) ^b			0.87	
Crossover	3	-7.29 (-13.86, -0.72) ^a	0.41	0.0	0.03	
		-7.29 (-13.86, -0.72) ^b			0.03	
Type of intervention						
Black tea leaf	8	-4.64 (-9.40, 0.13) ^a	0.29	17.6	0.06	
		-3.88 (-9.40, 1.64) ^b			0.17	
Black tea extract	4	-1.92 (-8.81, 4.96) ^a	0.04	63.8	0.58	
		-2.80 (-14.44, 8.83) ^b			0.64	
Duration						
>4 weeks (high median)	5	-3.18 (-10.70, 4.35) ^a	0.07	54.6	0.41	
		-1.96 (-13.58, 9.65) ^b			0.74	
≤4 weeks (low median)	7	-3.97 (-8.56, 0.61) ^a	0.21	28.2	0.09	
		-3.28 (-8.93, 2.37) ^b			0.26	
otal polyphenols dose						
>351.2 mg/d (high median)	2	-9.21 (-18.50, 0.07) ^a	0.11	60.6	0.052	
		-4.96 (-24.42, 14.50) ^b			0.62	
≤351.2 mg/d (low median)	3	-3.04 (-9.18, 3.11) ^a	0.19	40.1	0.33	
		-2.51 (-10.66, 5.65) ^b			0.55	
adad score						
Low (2, 3)	8	-0.92 (-5.82, 3.99) ^a	0.41	2.9	0.71	
		-0.79 (-5.82, 4.24) ^b			0.76	
High (≥4)	4	-8.74 (-15.24, -2.24) ^a	0.09	53.4	0.01	
		$-8.24(-18.09, 1.61)^{b}$			0.10	

^aThe result was obtained from a fixed-effects model;

^bThe result was obtained from a random-effects model.

doi:10.1371/journal.pone.0107711.t002

A previous meta-analysis pooling the data of observational studies suggested that 1 cup/d of green tea rather than black tea is correlated to a 10% reduction in the risk of coronary artery diseases development [38]. In addition, a large cohort study also found that green tea consumption, rather than black tea, is significantly associated with a decreased risk of mortality from CVD [39]. Recently, Zhao et al. conducted a meta-analysis investigating the effect of black tea on blood cholesterol concentrations on the basis of 10 RCTs. However, the overall meta-analysis and subgroup analyses of the study were based on the combined populations with different health status, which might limit the drawing of conclusions about the specific populations. In general, this meta-analysis indicated that black tea consumption has no significant effect on blood cholesterol concentrations, while a previous meta-analysis suggested that green tea consumption can

significantly lower the blood TC and LDL-C concentrations [15]. Therefore, black tea and green tea consumption might possess inconsistent effect on cholesterol concentrations and CVD risk. The null effect of black tea on blood cholesterol may be partly because black tea contains less antioxidant compounds than green tea [40]. Additionally, the amount and composition of catechins are substantially various between black tea and green tea due to the different degrees of fermentation. It has been reported that catechins constitute 80% to 90% of total green tea flavonoids, whereas they only constitute 20% to 30% of black tea flavonoids [41–43]. This is mainly due to the fact that black tea catechins are usually converted to some complex varieties, such as thearubigins and theaflavins during the oxidation process in the manufacture of black tea [14,43]. Animal studies have revealed that administration of catechins can significantly increase the activity of hepatic

Table 3. Subgroup analyses of effect of black tea on HDL-C concentrations in healthy subjects stratified by previously defined study characteristics.

Variables	HDL-C (mg/dL)					
	No. of comparisons	Net change(95% CI)	Test of he	eterogeneity	Р	
			Р	ŕ,%		
Baseline body mass index						
≥25 kg/m²	4	0.27 (-1.44, 1.99) ^a	0.77	0.0	0.76	
		0.27 (-1.44, 1.99) ^b			0.76	
<25 kg/m²	4	-0.68 $(-2.89, 1.53)^{a}$	0.37	3.7	0.55	
		-0.72 (-3.00, 1.56) ^b			0.54	
Study design						
Parallel	9	-0.87 (-2.85, 1.11) ^a	0.41	3.1	0.39	
		-0.93 (-2.99, 1.13) ^b			0.38	
Crossover	2	0.26 (-1.46, 1.99) ^a	0.62	0.0	0.76	
		0.26 (-1.46, 1.99) ^b			0.76	
Type of intervention						
Black tea leaf	7	-0.46 (-1.99, 1.07) ^a	0.21	28.8	0.56	
		-1.29 (-3.87, 1.29) ^b			0.33	
Black tea extract	4	0.36 (-2.08, 2.81) ^a	0.92	0.0	0.77	
		0.36 (-2.08, 2.81) ^b			0.77	
Duration						
>4 weeks (high median)	5	-1.08 (-4.79, 2.62) ^a	0.35	10.4	0.57	
-		-1.05 (-5.01, 2.91) ^b			0.60	
≤4 weeks (low median)	6	-0.11 (-1.49, 1.28) ^a	0.48	0.0	0.88	
		-0.11 (-1.49, 1.28) ^b			0.88	
Total polyphenols dose						
>351.2 mg/d (high median)	2	0.25 (-1.54, 2.03) ^a	0.29	10.9	0.79	
		-0.08 (-3.30, 3.15) ^b			0.96	
≤351.2 mg/d (low median)	3	$-0.54 (-2.87, 1.78)^{a}$	0.23	32.8	0.65	
		-0.78 (-3.85, 2.29) ^b			0.62	
Jadad score						
Low (2, 3)	7	-1.00 (-3.09, 1.08) ^a	0.24	24.5	0.35	
		-1.37 (-4.10, 1.36) ^b			0.33	
High (≥4)	4	0.27 (-1.39, 1.93) ^a	0.94	0.0	0.75	
2.7		$0.27 (-1.39 \cdot 1.93)^{b}$			0.75	

^aThe result was obtained from a fixed-effects model;

^bThe result was obtained from a random-effects model.

doi:10.1371/journal.pone.0107711.t003

LDL-receptor and reduce plasma and liver cholesterol concentrations [9,10]. In addition, Chan et al. suggested that catechins can inhibit cholesterol absorption by enhancing the cholesterol fecal excretion in hamsters [44]. Consistent with the animal studies, a previous *in vitro* study has suggested that catechins can directly inhibit the biosynthesis of cholesterol by selectively inhibiting the activity of squalene epoxidase [45]. Thus, if catechins account for the major beneficial effect of green tea on cholesterol concentrations [15], the comparatively lacking favorable effect of black tea on blood cholesterol concentrations is reasonable. In addition, all of the included studies selected participants with TC concentrations lower than 240 mg/dL, and most of the trials (14 of 15) included subjects with high concentrations of HDL-C (higher than 40 mg/dL). This may also partially explain the null effects of black tea on TC and HDL-C concentrations, because TC and HDL-C concentrations may fluctuate in a certain range in the subjects with normal cholesterol conditions [46]. Therefore, black tea consumption may not significantly affect the physiological regulation of blood cholesterol concentrations in these subjects. It has been suggested that the indirect calculation of LDL concentrations based on the Friedewald's formula, might generate uninterpretable calculated values in the participants with highly abnormal triglycerides [47]. In this meta-analysis, 4 studies [25,32,33,36] of the 15 included studies used Friedewald's formula to calculate LDL-C concentrations, and the remaining 11 studies used direct measuring method to detect LDL-C concentrations. However, the mean triglycerides concentrations of the subjects in the four studies ranged from 93 to 275 mg/dL, which may not be considered as highly abnormal [48]. It has been demonstrated that the results of direct measuring Table 4. Subgroup analyses of effect of black tea on LDL-C concentrations in healthy subjects stratified by previously defined study characteristics.

Variables	LDL-C (mg/dL)					
	No. of comparisons	Net change(95% CI)	Test of heterogeneity		Р	
			Р	ľ,%		
Baseline body mass index						
≥25 kg/m²	4	-6.32 (-13.21, 0.56) ^a	0.03	67.5	0.07	
		-0.87 (-14.69, 12.96) ^b			0.90	
<25 kg/m ²	4	-5.63 $(-10.74, -0.52)^{a}$	0.06	59.6	0.03	
		-6.31 (-14.97, 2.34) ^b			0.15	
Study design						
Parallel	9	-3.42 (-7.90, 1.07) ^a	0.15	33.8	0.14	
		-2.84 (-8.96, 3.29) ^b			0.36	
Crossover	2	$-12.45 (-20.45, -4.45)^{a}$	0.18	44.4	0.002	
		-10.75 (-23.16, 1.67) ^b			0.09	
Type of intervention						
Black tea leaf	7	-6.43 (-11.29, -1.57) ^a	0.27	20.9	0.01	
		-5.71 (-11.85, 0.43) ^b			0.07	
Black tea extract	4	-4.01 (-10.59, 2.57) ^a	0.02	69.0	0.23	
		-4.03 (-16.17, 8.12) ^b			0.52	
Duration						
>4 weeks (high median)	5	-7.46 (-14.73, -0.19) ^a	0.14	42.8	0.04	
		-6.89 (-17.39, 3.61) ^b			0.20	
≤4 weeks (low median)	6	-4.81 (-9.45, -0.17) ^a	0.07	51.3	0.04	
		-3.03 (-10.46, 4.39) ^b			0.42	
Total polyphenols dose						
>351.2 mg/d (high median)	2	-12.58 (-21.05, -4.11) ^a	0.09	66.2	0.004	
		-6.76 (-28.55, 15.04) ^b			0.54	
≤351.2 mg/d (low median)	3	-3.82 (-9.23, 1.59) ^a	0.19	40.6	0.17	
		-3.41 (-10.78, 3.96) ^b			0.37	
Jadad score						
Low (2, 3)	7	-1.20 (-6.41, 4.01) ^a	0.69	0.0	0.65	
		-1.20 (-6.41, 4.01) ^b			0.65	
High (≥4)	4	-11.22 (-17.13, -5.30) ^a	0.06	59.9	0.001	
-		$-10.13(-20.02) - 0.25)^{b}$			0.04	

^aThe result was obtained from a fixed-effects model;

^bThe result was obtained from a random-effects model.

doi:10.1371/journal.pone.0107711.t004

method (x) of LDL-C and the Friedewald's formula (y) were highly correlated (r = 0.9908, y = 1.030x - 0.289) when the TC concentrations ranged from 60 to 308 mg/dL [48]. Therefore, we did not exclude the studies using Friedewald's formula to calculate LDL-C concentrations and perform further analysis to investigate the influence of triglycerides concentrations on the meta-analysis on LDL-C concentrations.

Although we believe that this study provides useful findings, several inevitable limitations should be addressed. First, of the 15 studies, only 4 were identified as high-quality RCTs by Jadad scoring criteria, whereas the remaining 11 were of low-quality. This is mainly due to that 9 of 15 included studies used water as placebo in the control group, which is difficult for the researchers to conduct double-blinding.

Second, only one study provided the same background controlled diet to both intervention and control group during the study period. Most of the studies only suggested the participants keep their usual diet and limit consumption of black tea, caffeine, or polyphenols, etc. Due to the wide range and distribution of polyphenols in foods and drinks, the precise control of dietary intake in the original studies including free-living subjects was impossible. The differences in background dietary intake might bring confounding factors that affect the current results of this meta-analysis.

Third, we cannot independently conduct meta-analyses to explore the effect of black tea polyphenols on blood cholesterol concentrations because caffeine is naturally existed in black tea and there is limited information about the content of caffeine in most of the included studies. Therefore, it is hard for us to evaluate In addition, it is difficult for us to evaluate the interaction between black tea consumption and medicine use in subjects with diabetes or coronary artery diseases. However, none of the included studies reported significant unsafe effects of black tea on included participants. Moreover, measures of cholesterol were not the primary outcome in part of the RCTs reviewed in the metaanalysis and the null findings of secondary outcomes may not always be published.

In conclusion, this meta-analysis showed that black tea consumption may have no significant effect on TC, HDL-C, and LDL-C concentrations. Further high quality RCTs are needed to definitively draw a causal interpretation of the findings.

Supporting Information

Figure S1 Subgroup analyses of effect of black tea on TC concentrations in healthy subjects stratified by previously defined study characteristics based on the fixed-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference. (TIF)

Figure S2 Subgroup analyses of effect of black tea on TC concentrations in healthy subjects stratified by previously defined study characteristics based on the random-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference. (TIF)

Figure S3 Subgroup analyses of effect of black tea on HDL-C concentrations in healthy subjects stratified by previously defined study characteristics based on the fixed-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference. (TIF)

Figure S4 Subgroup analyses of effect of black tea on HDL-C concentrations in healthy subjects stratified by previously defined study characteristics based on the random-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference. (TIF)

Figure S5 Subgroup analyses of effect of black tea on LDL-C concentrations in healthy subjects stratified by

References

- World Health Organization (2012) Cardiovascular Disease: Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: WHO, 2012.
- Smith SC Jr, Collins A, Ferrari R, Holmes DR Jr, Logstrup S, et al. (2012) Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J Am Coll Cardiol 60: 2343–2348.

previously defined study characteristics based on the fixed-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference.

(TIF)

Figure S6 Subgroup analyses of effect of black tea on LDL-C concentrations in healthy subjects stratified by previously defined study characteristics based on the random-effects analysis. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome. NR, not report; WMD, weighted mean difference. (TIF)

Figure S7 Sensitivity analyses of effect of black tea on **TC concentrations in healthy subjects.** A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixed-effects or random-effects model. WMD, weighted mean difference. (TIF)

Figure S8 Sensitivity analyses of effect of black tea on HDL-C concentrations in healthy subjects. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixedeffects or random-effects model. WMD, weighted mean difference. (TIF)

Figure S9 Sensitivity analyses of effect of black tea on LDL-C concentrations in healthy subjects. A meta-analysis was done with STATA software (Version 11; StataCorp, College Station, TX). Weight of each study was shown by sizes of data markers in the analysis. The diamond represents the overall estimated outcome and the results were calculated using a fixedeffects or random-effects model. WMD, weighted mean difference. (TIF)

Appendix S1 A separate search strategy designed for each electronic database. (DOC)

Appendix S2 Supporting PRISMA Flow Diagram. (PDF)

Checklist S1 Supporting PRISMA checklist. (PDF)

Author Contributions

Conceived and designed the experiments: RKL DMW CHC. Performed the experiments: DMW CHC RKL. Analyzed the data: DMW CHC RKL. Contributed reagents/materials/analysis tools: RKL DMW CHC YW. Wrote the paper: RKL DMW CHC JXL.

- World Health Organization and World Economic Forum (2011) From Burden to "Best Buys": Reducing the Economic Impact of NCDs in Lowand Middle-Income Countries. Geneva, Switzerland: WHO, 2011.
- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–1847.

- Assmann G, Schulte H, von EA, Huang Y (1996) High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 Suppl: S11–20.
- Stamler J, Wentworth D, Neaton JD (1986) Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256: 2823–2828.
- (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374.
- Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, et al. (1980) Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol 46: 649–654.
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121: e46–46e215.
- Gyarfas I, Keltai M, Salim Y (2006) [Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study]. Orv Hetil 147: 675–686.
- Brunner E, White I, Thorogood M, Bristow A, Curle D, et al. (1997) Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials. Am J Public Health 87: 1415–1422.
- Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, et al. (2011) The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 57: 1299–1313.
- Song WO, Chun OK (2008) Tea is the major source of flavan-3-ol and flavonol in the U.S. diet. J Nutr 138: 1543S–1547S.
- Deka A, Vita JA (2011) Tea and cardiovascular disease. Pharmacol Res 64: 136– 145.
- Zheng XX, Xu YL, Li SH, Liu XX, Hui R, et al. (2011) Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr 94: 601–610.
- Peters U, Poole C, Arab L (2001) Does tea affect cardiovascular disease? A metaanalysis. Am J Epidemiol 154: 495–503.
- Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, et al. (2013) Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 6: CD009934.
- Zhao Y, Asimi S, Wu K, Zheng J, Li D (2014) Black tea consumption and serum cholesterol concentration: Systematic review and meta-analysis of randomized controlled trials.LID - S0261-5614(14)00167-8 [pii]LID - 10.1016/ j.clnu.2014.06.003 [doi]. Clin Nutr.
- Moher D, Pham B, Jones A, Cook DJ, Jadad AR, et al. (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 352: 609–613.
- Liu K, Xing A, Chen K, Wang B, Zhou R, et al. (2013) Effect of fruit juice on cholesterol and blood pressure in adults: a meta-analysis of 19 randomized controlled trials. PLOS ONE 8: e61420.
- 21. Higgins JP, Thompson SG, Decks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
- Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45: 769–773.
- Bahorun T, Luximon-Ramma A, Neergheen-Bhujun VS, Gunness TK, Googoolye K, et al. (2012) The effect of black tea on risk factors of cardiovascular disease in a normal population. Prev Med 54 Suppl: S98–102.
- Kubota K, Sumi S, Tojo H, Sumi-Inoue Y, I-Chin H, et al. (2011) Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-Erh) water extract. Nutr Res 31: 421–428.
- Neyestani TR, Shariatzade N, Kalayi A, Gharavi A, Khalaji N, et al. (2010) Regular daily intake of black tea improves oxidative stress biomarkers and decreases serum C-reactive protein levels in type 2 diabetic patients. Ann Nutr Metab 57: 40–49.
- 26. Trautwein EA, Du Y, Meynen E, Yan X, Wen Y, et al. (2010) Purified black tea theaflavins and theaflavins/catechin supplements did not affect serum lipids in

healthy individuals with mildly to moderately elevated cholesterol concentrations. Eur J Nutr 49: 27–35.

- Fujita H, Yamagami T (2008) Antihypercholesterolemic effect of Chinese black tea extract in human subjects with borderline hypercholesterolemia. Nutr Res 28: 450–456.
- Mukamal KJ, MacDermott K, Vinson JA, Oyama N, Manning WJ, et al. (2007) A 6-month randomized pilot study of black tea and cardiovascular risk factors. Am Heart J 154: 724.e1–6.
- Hodgson JM, Burke V, Beilin IJ, Croft KD, Puddey IB (2003) Can black tea influence plasma total homocysteine concentrations. Am J Clin Nutr 77: 907– 911.
- Davies MJ, Judd JT, Baer DJ, Clevidence BA, Paul DR, et al. (2003) Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J Nutr 133: 3298S–3302S.
- Hodgson JM, Puddey IB, Burke V, Watts GF, Beilin LJ (2002) Regular ingestion of black tea improves brachial artery vasodilator function. Clin Sci (Lond) 102: 195–201.
- Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, et al. (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104: 151–156.
- Duffy SJ, Vita JA, Holbrook M, Swerdloff PL, Keaney JF Jr (2001) Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21: 1084–1089.
- 34. Princen HM, van Duyvenvoorde W, Buytenhek R, Blonk C, Tijburg LB, et al. (1998) No effect of consumption of green and black tea on plasma lipid and antioxidant levels and on LDL oxidation in smokers. Arterioscler Thromb Vasc Biol 18: 833–841.
- Ishikawa T, Suzukawa M, Ito T, Yoshida H, Ayaori M, et al. (1997) Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification. Am J Clin Nutr 66: 261–266.
- Bingham SA, Vorster H, Jerling JC, Magee E, Mulligan A, et al. (1997) Effect of black tea drinking on blood lipids, blood pressure and aspects of bowel habit. Br J Nutr 78: 41–55.
- van het Hof KH, de Boer HS, Wiseman SA, Lien N, Westrate JA, et al. (1997) Consumption of green or black tea does not increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 66: 1125–1132.
- Wang ZM, Zhou B, Wang YS, Gong QY, Wang QM, et al. (2011) Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr 93: 506–515.
- Mineharu Y, Koizumi A, Wada Y, Iso H, Watanabe Y, et al. (2011) Coffee, green tea, black tea and oolong tea consumption and risk of mortality from cardiovascular disease in Japanese men and women. J Epidemiol Community Health 65: 230–240.
- Satoh E, Tohyama N, Nishimura M (2005) Comparison of the antioxidant activity of roasted tea with green, oolong, and black teas. Int J Food Sci Nutr 56: 551–559.
- Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea flavonoids. Crit Rev Food Sci Nutr 37: 693–704.
- Shahidi F (2000) Antioxidants in food and food antioxidants. Nahrung 44: 158– 163.
- Stangl V, Lorenz M, Stangl K (2006) The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res 50: 218–228.
- Chan PT, Fong WP, Cheung YL, Huang Y, Ho WK, et al. (1999) Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet. J Nutr 129: 1094–1101.
- Abe I, Šeki T, Umchara K, Miyase T, Noguchi H, et al. (2000) Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. Biochem Biophys Res Commun 268: 767–771.
- Carroll MD, Kit BK, Lacher DA, Yoon SS (2013) Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief: 1–8.
- Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
- Turkalp I, Cil Z, Ozkazanc D (2005) Analytical performance of a direct assay for LDL-cholesterol: a comparative assessment versus Friedewald's formula. Anadolu Kardiyol Derg 5: 13–17.